Recommended clinical usage and treatment course of Inavolisib

Inavolisib (Inavolisib) is a targeted therapy drug that is a PI3K inhibitor, especially for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer. Its clinical application is based on the presence of PIK3CA gene mutations, so mutation detection through blood samples is required before treatment. Only after the mutation has been confirmed by this test can Inaliside be selected as part of the treatment regimen.

Preparation before administration is crucial. First, patients need to be tested for fasting blood glucose (FPG), blood glucose (FBG) and glycated hemoglobin (HbA1c). These indicators help evaluate the patient's metabolic status, ensure that the patient's blood sugar level is properly controlled during treatment, and avoid metabolic abnormalities caused by drug side effects.

In terms of dose selection, the recommended dose of inaliset is9 mg, taken orally once daily. Patients can choose to take it before or after meals, but it is important to note that the tablets must be swallowed whole and must not be chewed, crushed or broken. If the patient forgets a dose after taking the medicine, he should try to take it within 9 hours. If it exceeds 9 hours, skip the dose and take the medicine at the originally scheduled time. If vomiting occurs after taking the medicine, there is no need to take more medicine on the same day, and you can continue taking the medicine at the regular time the next day.

Inaliset is often used in combination with other drugs, such as palbociclib and fulvestrant. In this combination therapy, the recommended dose of palbociclib is 125 mg once daily with a 7-day break after 21 days, constituting a 28-day treatment cycle. Fulvestrant is often used as a hormonal therapy together with inaliset to enhance the therapeutic effect.

In general, treatment courses with inaliset are usually continued until disease progression or the patient develops unacceptable toxicity. During the treatment period, patients need to undergo regular examinations, especially monitoring of blood sugar, so that the treatment plan can be adjusted in a timely manner.

Keyword tags:

Inalise, recommended clinical usage, targeted drugs, PIK3CA mutations, breast cancer, drug dosage, combination medication, cancer treatment

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107